Crispr Therapeutics AG (1CG)

40.0000
0.0000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    41.0000/41.2000
  • Day's Range:
    39.4000 - 40.0000
  • Type:Equity
  • Market:Germany
  • ISIN:CH0334081137
  • WKN:A2AT0Z

1CG Comments

What is your sentiment on CRISPR Therapeutics AG?
or
Market is currently closed. Voting is open during market hours.

All Comments

(156)
  • 97 usd  is a good entry point...
    2
    • a classic Cathy wood collapse
      6
      • how do you actually buy shares i have a buy sell window open but its an ad i wanna actually buy a stock not be sent to yet another bs broker app
        0
        • Check if you Bank can help you out
          0
        • Open and fund a brokerage account. There are many options.
          0
      • wow
        0
        • Beat on earnings!! Largly
          0
          • Problem with this one is you're gonna need to wait a literal decade for it to be viable, regardless of studies/tests.
            0
            • true
              0
            • I think in a normal world… Definitely. My opinion, it right around the corner.
              0
          • total bubble of cathie wollod pump
            3
            • CRSP and AIRI are Good stockAIRI will go up to X3
              0
              • keep on dropping...
                0
                • good entry point is around 80
                  2
                  • keep dropping, want to get back in
                    0
                    • 206 by Oct
                      1
                      • That would be acceptable.
                        0
                    • Last weekend, Intellia Therapeutics and Regeneron announced first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome editing in humans. We summarise the findings here.
                      0
                      • ride it to new highs
                        0
                        • Alert: Crispr Therapeutics will acquire AGTC before end of FY2021 as a strategy to get into the ophthalmology space. Load up now & Stay tuned
                          0
                          • ok, thanks
                            0
                          • Thank you, but may we know your source, please?
                            0
                          • What proof or source do you have that these facts have changed? See quote:  Gene therapy developer AGTC lost nearly half its market cap Thursday morning after Biogen exited a collaboration agreement on the heels of a big clinical failure. Interim six-month data on one of AGTC's investigational therapies showed it was generally safe but ineffective at treating a rare eye disorder known as X-linked retinoschisis (XLRS). The company plans to complete patient monitoring activities on the XLRS program but will not develop it further.
                            0
                        • Held the dip, looks great
                          0
                          • i think that someone knew the news about intellia on friday already and then bought Crispr quickly.
                            0
                            • i thought the same.. lucky enough it was good news
                              0
                          • ouch...shorts are about to get crushed
                            0
                            • It will most likely go higher on monday due to good results from Intellia.
                              0
                              • Any reason why it's up over 5% today?
                                0
                                • lander.gates.fauci
                                  0
                                  • buying more around $100
                                    1
                                    • Thank you for your insight...please take your seat now.
                                      0
                                  • short squeeze coming
                                    1
                                    • https://www.businesswire.com/news/home/20210611005069/en/Vertex-and-CRISPR-Therapeutics-Present-New-Data-in-22-Patients-With-Greater-Than-3-Months-Follow-Up-Post-Treatment-With-Investigational-CRISPRCas9-Gene-Editing-Therapy-CTX001%E2%84%A2-at-European-Hematology-Association-Annual-Meeting
                                      0
                                      • Good n3ws is coming . About to breakout to $130
                                        1
                                        • There are two health care conferences on Jun 8 and Jun 11. I am expecting good news about crsp from both conferences.
                                          0
                                        • Ongoing CLIMB SCD-121 Study of Autologous Crispr-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells,” will be made available on the virtual platform as an e-poster Friday, June 11 at
                                          0
                                        • Well done, Rajesh Kumar!
                                          0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.